The Efficacy and Safety of Etrasimod for the Induction and Maintenance of Remission in Moderate to Severe Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials
The findings of this meta-analysis support Etrasimod as an effective and well-tolerated treatment option for achieving and maintaining remission in patients with moderate to severe UC.
Abstract
Etrasimod is a selective sphingosine 1-phosphate (S1P) receptor modulator that is used as a novel oral treatment for moderate to severe ulcerative colitis (UC). The efficacy and safety of Etrasimod across both induction and maintenance treatment phases require further evaluation. An extensive search was conducted across PubMed, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials (CENTRAL), identifying seven reports of five independent randomised controlled trials (RCTs) comprising 1230 participants across multiple countries to be included in this meta-analysis. Data analysis was carried out using a fixed-effects model, with results reported as risk ratios (RRs) and 95% confidence intervals (CIs). Etrasimod significantly increased the likelihood of clinical remission at Week 12 (RR 2.63; 95% CI: 1.91, 3.62; p-value < 0.00001) and beyond 40 weeks (RR 2.87; 95% CI: 1.89, 4.37; p-value < 0.00001). Clinical response also improved significantly at Week 12 (RR 1.68; 95% CI: 1.44, 1.95; p-value < 0.00001) and beyond 40 weeks (RR 1.73; 95% CI: 1.35, 2.21; p-value < 0.0001). Etrasimod significantly improved endoscopic outcomes at Week 12 (RR 2.15; 95% CI: 1.67, 2.75; p-value < 0.00001) and beyond 40 weeks (RR 2.57; 95% CI: 1.79, 3.68; p-value < 0.00001). Significant improvements were also observed in symptomatic remission at Week 12 (RR 1.81; 95% CI: 1.47, 2.24; p-value < 0.00001) and beyond 40 weeks (RR 1.96; 95% CI: 1.47, 2.61; p-value < 0.00001), as well as mucosal healing at Week 12 (RR 2.67; 95% CI: 1.77, 4.02; p-value < 0.00001) and beyond 40 weeks (RR 2.62; 95% CI: 1.69, 4.04; p-value < 0.0001). Steroid-free clinical remission was also significantly more likely with Etrasimod (RR 3.83; 95% CI: 2.21, 6.62; p-value < 0.00001). No statistically significant difference was observed in serious adverse events between Etrasimod and placebo (RR 1.06; 95% CI: 0.61, 1.85; p-value = 0.83), although a small increase in other adverse events was observed with Etrasimod (RR 1.15; 95% CI: 1.03, 1.28; p-value = 0.01). No deaths were reported in either treatment group. The findings of this meta-analysis support Etrasimod as an effective and well-tolerated treatment option for achieving and maintaining remission in patients with moderate to severe UC. Further research will help to better understand the long-term effects and safety of Etrasimod in patients with different disease characteristics, comorbidities and potential drug interactions.
Objective: Mirikizumab, a p19-directed anti-interleukin-23 monoclonal antibody, has been evaluated as induction and maintenance therapy for moderately to severely active ulcerative colitis (UC). We conducted a systematic review and meta-analysis of randomized, placebo-controlled trials to quantify its efficacy and safe...
G. Dağcı, A. Sarıca, B. F. Ağargün et al.· Journal of Enterocolitis· 0 citations
BACKGROUND & AIMS
Advanced therapies (ATs) are central to the management of moderate-to-severe ulcerative colitis (UC). The expanding therapeutic landscape and limited head-to-head trials necessitate updated comparative effectiveness analyses. We performed a systematic review and network meta-analysis (NMA) to assess t...
Pablo A. Olivera, Juan S. Lasa, Siddharth Singh et al.· Clinical Gastroenterology an...· 0 citations
Objective To evaluate the cutaneous efficacy and glucocorticoid-sparing effects of anifrolumab in systemic lupus erythematosus (SLE) and to assess composite disease activity and flare-related and safety outcomes. Methods PubMed, Embase, Web of Science, the Cochrane Library, and ClinicalTrials.gov were searched through...
Jia-Ni Wang, Fei Liu, Q. Lou et al.· Frontiers in Immunology· 0 citations
Introduction: Remogliflozin is a sodium–glucose cotransporter-2 inhibitor used for type 2 diabetes mellitus (T2DM), but its overall efficacy and safety remain fragmented. This updated systematic review and meta-analysis evaluated the efficacy and safety of remogliflozin using evidence exclusively from randomized contro...
N. Kostadinov, T. Totomirova, Z. Kirovakov et al.· Endocrines· 0 citations
Oral icotrokinra significantly improved physician-assessed and psoriasis area and severity index (PASI) responses compared with control in RCTs and offers rapid and clinically significant improvements in plaque psoriasis, particularly on IGA and PASI, and these responses continue to improve over time.
M. Alkharisi, Yara Ayman Zein, F. Alammari et al.· Annals of Middle Eastern Med...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.